

**GYNECOLOGIC CANCER INTERGROUP  
(GCIG)  
META-ANALYSIS WORKING GROUP**

**Project Proposal**

**J PAUL SGCTG**



SCOTROC4\* demonstrated a statistically significant prognostic value for PFS for the following haematological parameters in a multivariable model:-

❖ Baseline neutrophils

❖ Difference between WBC and baseline neutrophils

❖ Baseline platelets

The multivariable model also included the following clinical factors:-

Performance status; stage; bulk of residual disease; type (epithelial, peritoneal, fallopian); bulk of residual disease; elevated CA125

\*Ann Oncol. 2013 Mar;24(3):679-87. Banerjee S, Rustin G, Paul J et al  
A multicenter, randomized trial of flat dosing versus inpatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCI

# Proposal

- ❖ Use the meta-analysis database to build a prognostic model for OS and PFS incorporating baseline haematological parameters and the clinical factors identified in the SCOTROC4 paper. This would be done in a development subset
- ❖ The model building would also explore the value of baseline biochemistry parameters previously identified as prognostic e.g. albumin and alk. phos. (Clark TG, Stewart ME, Altman DG, et al: A prognostic model for ovarian cancer. Br J Cancer 85::944,2001-952)
- ❖ To validate the model using a validation subset taken from meta-analysis database using appropriate methodology (e.g. Altman Douglas G, Vergouwe Yvonne, Royston Patrick, Moons Karel G M. Prognosis and prognostic research: validating a prognostic model *BMJ* 2009; 338 :b605)
- ❖ As part of the validation to quantify the contribution of the haematological parameters to the prognostic ability of the model
- ❖ Develop an validated online prognostic score based on the multivariable model for use in the clinic